HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
PVLA
Palvella Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $1.51B
Market Cap
$1.51B
Enterprise Val
$1.25B
P/E Ratio
-30.56
P/B Ratio
6.48
Trailing PEG (1Y)
-0.49
As Of
Jun 7, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$232.3M
Return on Equity-56.87%
Return on Assets-42.50%
Current Ratio28.88
Debt/Equity0.00
LT Debt/Equity0.00
Revenue Per Share0.00

Income Statement

Mar 31, 2026
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$9.3M
SG&A$5.5M
Operating Expenses$14.9M
Operating Income-$14.9M
Interest Expense$2.0M
Tax Expense$0.00
Net Income-$15.8M
EPS (Basic)$-1.20
EPS (Diluted)$-1.20
EBIT-$13.7M
EBITDA-$13.7M
Consolidated Income-$15.8M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$206.4M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$263.2M
LT Investments$0.00
Property, Plant & Equipment$528.0K
Intangibles$0.00
Non-Current Assets$528.0K
Total Assets$263.8M
Accounts Payable$5.4M
Current Debt$209.0K
Current Liabilities$9.1M
LT Debt$375.0K
Non-Current Liabilities$22.3M
Total Liabilities$31.4M
Total Debt$584.0K
Retained Earnings-$151.2M
Shareholder Equity$232.3M
Shares Outstanding14,313,659

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$10.9M
Investing Cash Flow-$55.4M
Financing Cash Flow$214.7M
CapEx$0.00
Free Cash Flow-$10.9M
Depreciation & Amort.$44.0K
Stock-Based Comp$3.4M
Acquisitions / Disposals$0.00
Investment Activity-$55.4M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$216.7M
Dividends Paid$0.00
Net Change in Cash$148.4M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h